Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Cash from Operations (2017 - 2022)

Historic Cash from Operations for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to -$4.3 million.

  • Iterum Therapeutics' Cash from Operations fell 7344.45% to -$4.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$18.5 million, marking a year-over-year decrease of 1660.78%. This contributed to the annual value of -$26.8 million for FY2024, which is 3193.49% up from last year.
  • As of Q4 2022, Iterum Therapeutics' Cash from Operations stood at -$4.3 million, which was down 7344.45% from -$4.5 million recorded in Q3 2022.
  • Over the past 5 years, Iterum Therapeutics' Cash from Operations peaked at -$1.1 million during Q1 2021, and registered a low of -$27.5 million during Q3 2018.
  • In the last 5 years, Iterum Therapeutics' Cash from Operations had a median value of -$10.3 million in 2018 and averaged -$12.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 40570.17% in 2018, then surged by 9586.73% in 2021.
  • Iterum Therapeutics' Cash from Operations (Quarter) stood at -$25.2 million in 2018, then increased by 8.47% to -$23.1 million in 2019, then surged by 60.83% to -$9.0 million in 2020, then skyrocketed by 72.77% to -$2.5 million in 2021, then crashed by 73.44% to -$4.3 million in 2022.
  • Its last three reported values are -$4.3 million in Q4 2022, -$4.5 million for Q3 2022, and -$6.3 million during Q2 2022.